Targeted Coaching to Improve Osteoporosis Therapy Adherence: A Single Arm Variation of the C-STOP Study

Overview

Journal J Bone Metab

Date 2024 Mar 14

PMID 38485237

Authors

Carrie Ye

Finlay A McAlister

Debbie Bellerose

Meng Lin

Affiliations

Soon will be listed here.

Abstract

Background: In this pre-planned variation of the Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP) trial, we investigated whether adherence-specific coaching by the case manager (CM) further improved the adherence and persistence rates compared to those seen in the C-STOP trial.

Methods: We conducted a prospective observational cohort study of community-dwelling adults 50 years or older who suffered an upper-extremity fracture and were not previously treated with osteoporosis medications, to assess whether a well-trained CM can partner with patients to improve adherence to and persistence with oral bisphosphonate intake. The primary outcome was adherence (taking > 80% of prescribed doses) to oral bisphosphonate intake at 12 months after study enrollment. Secondary outcomes included primary adherence to and 12-month persistence with oral bisphosphonate and calcium and vitamin D supplement intake at 12 months.

Results: The study cohort consisted of 84 participants, of which 30 were prescribed an oral bisphosphonate. Twenty-two (73.3%) started treatment within 3 months. The adherence rate at 12 months was 77.3%. The persistence rate at 12 months was 95.5%. Of those not prescribed an oral bisphosphonate, 62.8% were taking supplemental calcium and 93.0% were taking supplemental vitamin D at 12 months. Depression was a significant predictor of 12-month non-adherence (adjusted odds ratio, 9.8; 95% confidence interval, 1.2-81.5).

Conclusions: Adherence-specific coaching by a CM did not further improve the level of medication adherence achieved in the original C-STOP study. Importantly, these results can inform adherence in future intervention studies.

References

Yeam C, Chia S, Tan H, Kwan Y, Fong W, Seng J . A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018; 29(12):2623-2637. DOI: 10.1007/s00198-018-4759-3. View

Armstrong P, McAlister F . Searching for Adherence: Can We Fulfill the Promise of Evidence-Based Medicines?. J Am Coll Cardiol. 2016; 68(8):802-4. DOI: 10.1016/j.jacc.2016.06.006. View

Sagalla N, Lee R, Lyles K, Vognsen J, Colon-Emeric C . Extent of and reasons for osteoporosis medication non-adherence among veterans and feasibility of a pilot text message reminder intervention. Arch Osteoporos. 2021; 16(1):21. PMC: 8300873. DOI: 10.1007/s11657-021-00889-7. View

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate J . Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2009; 21(11):1943-51. DOI: 10.1007/s00198-009-1134-4. View

Kanis J, Johnell O, De Laet C, Johansson H, Oden A, Delmas P . A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35(2):375-82. DOI: 10.1016/j.bone.2004.03.024. View

Majumdar S, Johnson J, McAlister F, Bellerose D, Russell A, Hanley D . Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ. 2008; 178(5):569-75. PMC: 2244663. DOI: 10.1503/cmaj.070981. View

McAlister F, Ye C, Beaupre L, Rowe B, Johnson J, Bellerose D . Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. Osteoporos Int. 2018; 30(1):127-134. DOI: 10.1007/s00198-018-4702-7. View

Grenard J, Munjas B, Adams J, Suttorp M, Maglione M, McGlynn E . Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med. 2011; 26(10):1175-82. PMC: 3181287. DOI: 10.1007/s11606-011-1704-y. View

Majumdar S, McAlister F, Johnson J, Rowe B, Bellerose D, Hassan I . Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP Trial): A Randomized Controlled Trial. J Bone Miner Res. 2018; 33(12):2114-2121. DOI: 10.1002/jbmr.3557. View

10.

Wozniak L, Johnson J, McAlister F, Beaupre L, Bellerose D, Rowe B . Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment. Osteoporos Int. 2016; 28(1):219-229. PMC: 5206259. DOI: 10.1007/s00198-016-3693-5. View

11.

Koller G, Goetz V, Vandermeer B, Homik J, McAlister F, Kendler D . Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020; 31(11):2093-2102. DOI: 10.1007/s00198-020-05507-9. View

12.

Ye C, Schousboe J, Morin S, Lix L, Leslie W . Time since prior fracture affects mortality at the time of clinical assessment: a registry-based cohort study. Osteoporos Int. 2022; 33(6):1257-1264. DOI: 10.1007/s00198-021-06236-3. View

13.

Majumdar S, Johnson J, Lier D, Russell A, Hanley D, Blitz S . Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int. 2006; 18(3):261-70. DOI: 10.1007/s00198-006-0248-1. View

14.

Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S . 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182(17):1864-73. PMC: 2988535. DOI: 10.1503/cmaj.100771. View

15.

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D . Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44-7. DOI: 10.1111/j.1524-4733.2007.00213.x. View

16.

Langsetmo L, Goltzman D, Kovacs C, Adachi J, Hanley D, Kreiger N . Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res. 2009; 24(9):1515-22. PMC: 5101057. DOI: 10.1359/jbmr.090319. View